Minori Enomoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minori Enomoto has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kazuo Mishima
Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan
3 shared publications - Shingo Kitamura
Department of Sleep-Wake Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan
3 shared publications - Akiko Hida
Department of Sleep-Wake Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry Tokyo Japan
2 shared publications - Kentaro Nozaki
Counseling Room Higashimatsuyama Japan
2 shared publications - Makiko Watanabe
National Graduate Institute for Policy Studies, Tokyo, Japan
2 shared publications - Shigekazu Higuchi
Kyushu University
2 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Springer Nature in Journal of Physiological Anthropology
- Vol. 45 (1)
Effects of later dinner timing on subsequent metabolic function and nocturnal sleep in healthy young women
Objectives: This study aimed to investigate the effects of dinner timing on subsequent sleep architecture and glucose metabolism in healthy young women, using objective and integrated physiological measures in a real-life setting. Methods: We conducted a randomized crossover trial with two dinner timing conditions: 1 h and 5 h before habitual bedtime. Each intervention lasted 6 days (Day 0 to Day 5), including a baseline day (Day 0) and 4 intervention days (Days 1–4). Dinner provided 709–740 kcal, with consistent macronutrient composition across conditions. Overnight sleep electroencephalography (EEG) was recorded on Day 0 and Day 4, and continuous glucose monitoring (CGM) was conducted throughout the experimental period. An oral glucose tolerance test (OGTT) was performed after waking on Day 5. Results: Thirteen healthy young women (21.4 ± 0.6 years) participated. On Day 4, the late-dinner condition (1 h before bedtime) resulted in significantly shorter total sleep time (TST, p = 0.013) and reduced sleep efficiency (SE, p = 0.040) and significantly higher wake after sleep onset (WASO, p = 0.017), Arousal Index ( p = 0.041), number of stage-shifts ( p = 0.016), and Stage-Shift Index ( p = 0.003). The iAUC for postprandial glucose showed a significant interaction ( p = 0.042), with lower values on Days 3 and 4 than on Day 1 ( p = 0.090). OGTT results showed no significant changes. Conclusion: Dinner consumed 1 h before bedtime was associated with reduced sleep continuity and stability, while only transient changes in postprandial glucose dynamics were observed. In healthy young women, eating close to bedtime may affect sleep architecture, warranting further investigation.
- 13 April 2026
- Published by Springer Nature in Journal of Physiological Anthropology
- Vol. 45 (1)
Open AccessEffects of later dinner timing on subsequent metabolic function and nocturnal sleep in healthy young women
Objectives: This study aimed to investigate the effects of dinner timing on subsequent sleep architecture and glucose metabolism in healthy young women, using objective and integrated physiological measures in a real-life setting. Methods: We conducted a randomized crossover trial with two dinner timing conditions: 1 h and 5 h before habitual bedtime. Each intervention lasted 6 days (Day 0 to Day 5), including a baseline day (Day 0) and 4 intervention days (Days 1–4). Dinner provided 709–740 kcal, with consistent macronutrient composition across conditions. Overnight sleep electroencephalography (EEG) was recorded on Day 0 and Day 4, and continuous glucose monitoring (CGM) was conducted throughout the experimental period. An oral glucose tolerance test (OGTT) was performed after waking on Day 5. Results: Thirteen healthy young women (21.4 ± 0.6 years) participated. On Day 4, the late-dinner condition (1 h before bedtime) resulted in significantly shorter total sleep time (TST, p = 0.013) and reduced sleep efficiency (SE, p = 0.040) and significantly higher wake after sleep onset (WASO, p = 0.017), Arousal Index ( p = 0.041), number of stage-shifts ( p = 0.016), and Stage-Shift Index ( p = 0.003). The iAUC for postprandial glucose showed a significant interaction ( p = 0.042), with lower values on Days 3 and 4 than on Day 1 ( p = 0.090). OGTT results showed no significant changes. Conclusion: Dinner consumed 1 h before bedtime was associated with reduced sleep continuity and stability, while only transient changes in postprandial glucose dynamics were observed. In healthy young women, eating close to bedtime may affect sleep architecture, warranting further investigation.
- 17 July 2025
- Published by Taylor & Francis in Chronobiology International
- Vol. 42 (9) , 1137-1144
External validation of the Japanese version of the reduced morningness-eveningness questionnaire (rMEQ) score using dim light melatonin onset and sleep-wake behavior in young adults
The Reduced Morningness-Eveningness Questionnaire (rMEQ), a five-item version of the 19-item MEQ, is a practical tool for assessing circadian typology or "morningness" and "eveningness" preference. Although we previously validated the Japanese version of rMEQ with MEQ, external validation against an established standard was lacking. This study aimed to additionally validate the Japanese rMEQ in young adults by assessing the dim light melatonin onset (DLMO), a marker of circadian phase, and subjective/objective sleep-wake habits. Twenty healthy young adults (mean age: 23.0 ± 1.9 years) participated in this study and were assessed the circadian typology by rMEQ and MEQ. The sleep-wake habits were measured by sleep diary, actigraphy and the Pittsburgh Sleep Quality Index (PSQI). Salivary melatonin samples were collected to determine DLMO. Results showed significant correlations between rMEQ scores and DLMO, as well as sleep variables based on sleep diary, actigraphy and PSQI. Correlations between rMEQ scores and these variables were consistently stronger than those for MEQ. These findings highlight the validity of the Japanese rMEQ and that the rMEQ more accurately reflects circadian typology and internal circadian phases compared to MEQ, at least in Japanese young adults. The Japanese rMEQ could be a valuable tool for efficiently assessing circadian typologies in Japanese young adults.
- 17 July 2025
- Published by Taylor & Francis in Chronobiology International
- Vol. 42 (9) , 1137-1144
External validation of the Japanese version of the reduced morningness-eveningness questionnaire (rMEQ) score using dim light melatonin onset and sleep-wake behavior in young adults
The Reduced Morningness-Eveningness Questionnaire (rMEQ), a five-item version of the 19-item MEQ, is a practical tool for assessing circadian typology or "morningness" and "eveningness" preference. Although we previously validated the Japanese version of rMEQ with MEQ, external validation against an established standard was lacking. This study aimed to additionally validate the Japanese rMEQ in young adults by assessing the dim light melatonin onset (DLMO), a marker of circadian phase, and subjective/objective sleep-wake habits. Twenty healthy young adults (mean age: 23.0 ± 1.9 years) participated in this study and were assessed the circadian typology by rMEQ and MEQ. The sleep-wake habits were measured by sleep diary, actigraphy and the Pittsburgh Sleep Quality Index (PSQI). Salivary melatonin samples were collected to determine DLMO. Results showed significant correlations between rMEQ scores and DLMO, as well as sleep variables based on sleep diary, actigraphy and PSQI. Correlations between rMEQ scores and these variables were consistently stronger than those for MEQ. These findings highlight the validity of the Japanese rMEQ and that the rMEQ more accurately reflects circadian typology and internal circadian phases compared to MEQ, at least in Japanese young adults. The Japanese rMEQ could be a valuable tool for efficiently assessing circadian typologies in Japanese young adults.
- Open Access
- 13 March 2021
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 8 (3) , 277-288
Prescribing Pattern of Hypnotic Medications in Patients Initiating Treatment at Japanese Hospitals: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Claims Database
Background Prolonged treatment of insomnia using benzodiazepine (BZD) receptor agonists, including BZD and non-BZD hypnotic drugs, can cause drug dependence, tolerance, abuse and other adverse events. These side effects are more common and/or severe in older adults taking different hypnotic drugs concomitantly. Therefore, a single prescription is limited to 30 daily doses for most BZD receptor agonists and restrictions apply to the prescription of more than three types of hypnotic drugs in Japan. Little is known, however, about the real-world prescribing pattern of hypnotic drugs in Japan. Objective We analysed prescribing patterns for hypnotic drugs in Japan to evaluate whether real-world use differs from guideline recommendations. Methods In this nationwide, retrospective, longitudinal, observational study, we analysed the types of hypnotic drugs prescribed, duration of medication and treatment setting in a subset of hospitals in Japan using a hospital-based administrative claims database (Medical Data Vision). Patients initiating treatment with hypnotic drugs between January 2012 and December 2016 were included in the analyses to assess the duration of medication and occurrence of co-prescription of a second and third hypnotic drug, within a year from prescription of the first hypnotic drugs. Results In 261,167 patients analysed, the first hypnotic drugs prescribed were BZDs (59.7%), non-BZDs (36.8%), a melatonin receptor agonist [MRA] (3.1%) and an orexin receptor antagonist [ORA] (0.4%). Benzodiazepine and non-BZD hypnotic drugs were mostly prescribed in inpatient settings (57.7% and 63.0%, respectively) and the MRA and ORA mostly in outpatient settings (62.6% and 65.4%, respectively). The departments that prescribed the most patients their first hypnotic drugs were internal medicine (23.6%), general surgery (11.8%), orthopaedic surgery (11.4%) and urology (5.3%). Of the total prescriptions of MRA and ORA as the first hypnotic drugs, 22.0% and 31.8% were in internal medicine, 4.4% each in general surgery, 6.0% and 4.5% in orthopaedic surgery, 9.7% and 4.4% in neurology, and 10.1% and 12.2% in psychiatry departments, respectively. Mean duration of medication was 1.13 months for non-BZDs, 1.15 months for BZDs, 1.29 months for the ORA and 1.83 months for the MRA. Overall, 5.3% (95% confidence interval 5.2–5.4) of patients were prescribed a second hypnotic drug; of these, 8.4% (95% confidence interval 8.0–8.9) were prescribed at least three hypnotic drugs within a year. Patients who were prescribed three or more hypnotic drugs received higher doses of the first drug than patients who received fewer hypnotic drugs. Conclusions Benzodiazepine receptor agonists were the most common hypnotic drugs prescribed as the first drug to patients in Japan. Further education and awareness may be needed on the risk of complications and adverse events associated with these therapies. The duration of BZD receptor agonist use was shorter than for the MRA and ORA, in accordance with prescribing guidelines. Long-term use and co-prescribing of hypnotic drugs were also uncommon.
- 13 March 2021
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 8 (3) , 277-288
Open AccessPrescribing Pattern of Hypnotic Medications in Patients Initiating Treatment at Japanese Hospitals: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Claims Database
Background Prolonged treatment of insomnia using benzodiazepine (BZD) receptor agonists, including BZD and non-BZD hypnotic drugs, can cause drug dependence, tolerance, abuse and other adverse events. These side effects are more common and/or severe in older adults taking different hypnotic drugs concomitantly. Therefore, a single prescription is limited to 30 daily doses for most BZD receptor agonists and restrictions apply to the prescription of more than three types of hypnotic drugs in Japan. Little is known, however, about the real-world prescribing pattern of hypnotic drugs in Japan. Objective We analysed prescribing patterns for hypnotic drugs in Japan to evaluate whether real-world use differs from guideline recommendations. Methods In this nationwide, retrospective, longitudinal, observational study, we analysed the types of hypnotic drugs prescribed, duration of medication and treatment setting in a subset of hospitals in Japan using a hospital-based administrative claims database (Medical Data Vision). Patients initiating treatment with hypnotic drugs between January 2012 and December 2016 were included in the analyses to assess the duration of medication and occurrence of co-prescription of a second and third hypnotic drug, within a year from prescription of the first hypnotic drugs. Results In 261,167 patients analysed, the first hypnotic drugs prescribed were BZDs (59.7%), non-BZDs (36.8%), a melatonin receptor agonist [MRA] (3.1%) and an orexin receptor antagonist [ORA] (0.4%). Benzodiazepine and non-BZD hypnotic drugs were mostly prescribed in inpatient settings (57.7% and 63.0%, respectively) and the MRA and ORA mostly in outpatient settings (62.6% and 65.4%, respectively). The departments that prescribed the most patients their first hypnotic drugs were internal medicine (23.6%), general surgery (11.8%), orthopaedic surgery (11.4%) and urology (5.3%). Of the total prescriptions of MRA and ORA as the first hypnotic drugs, 22.0% and 31.8% were in internal medicine, 4.4% each in general surgery, 6.0% and 4.5% in orthopaedic surgery, 9.7% and 4.4% in neurology, and 10.1% and 12.2% in psychiatry departments, respectively. Mean duration of medication was 1.13 months for non-BZDs, 1.15 months for BZDs, 1.29 months for the ORA and 1.83 months for the MRA. Overall, 5.3% (95% confidence interval 5.2–5.4) of patients were prescribed a second hypnotic drug; of these, 8.4% (95% confidence interval 8.0–8.9) were prescribed at least three hypnotic drugs within a year. Patients who were prescribed three or more hypnotic drugs received higher doses of the first drug than patients who received fewer hypnotic drugs. Conclusions Benzodiazepine receptor agonists were the most common hypnotic drugs prescribed as the first drug to patients in Japan. Further education and awareness may be needed on the risk of complications and adverse events associated with these therapies. The duration of BZD receptor agonist use was shorter than for the MRA and ORA, in accordance with prescribing guidelines. Long-term use and co-prescribing of hypnotic drugs were also uncommon.
- 1 September 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e168
Circadian functions in patients with circadian rhythm sleep disorder (free-running type) and healthy controls
- 1 September 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e168
Circadian functions in patients with circadian rhythm sleep disorder (free-running type) and healthy controls
- 19 August 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e168-e169
Surrogate measurements for assessing individual's circadian clock properties
- 19 August 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e168-e169
Surrogate measurements for assessing individual's circadian clock properties